Applying Data‐Independent Acquisition Mass Spectrometry on Cerebrospinal Fluid Samples from a Neurology Clinic for Biomarker Discovery in Alzheimer’s Disease

Diagnosis of Alzheimer’s disease (AD) primarily relies on cognitive assessments combined with imaging and limited fluid biomarkers. These biomarkers do not correlate with cognitive prognosis. Analysis of larger sets of biomarkers could improve diagnosis and prognosis of AD and differentiate between comorbid pathophysiologies, and measure treatment efficacy. Here, we report analysis of a Data‐independent Acquisition (DIA) mass‐spectrometry method used to simultaneously quantify hundreds of proteins in a large‐scale patient cohort. We aim to define markers that are able to stratify and diagnose AD in this clinically complex cohort.